CNSystems receives FDA approval for CNAP blood pressure monitor
10 November 2008
Austrian company CNSystems Medizintechnik AG, has received US FDA
approval to market its CNAP Monitor 500 in the United States.
The CNAP Monitor 500 measures non-invasive and continuous blood
pressure in real-time and can predict responsiveness to fluid
In the perioperative setting, detecting blood pressure drops and
their cause in time is crucial for peri- and postoperative outcome.
However, until recently only invasive methods provided quality
information to the clinician.
CNSystems says that CNAP provides reliable blood pressure monitoring
comparable to invasive techniques and adds valuable information about
fluid responsiveness of the patient non-invasively. This allows
spreading the highest level of blood pressure monitoring to all
perioperative settings where close blood pressure monitoring is
indicated, but the risk and discomfort of invasive measurement is not
“CNAP has been very well received amongst Europe’s anesthesiologists
in only a short time,” commented Dr Juergen Fortin, CEO of CNSystems,
“and we are confident that the same will be true in the USA where the
perioperative market for continuous non-invasive blood pressure control
is even more promising, with an estimated sales potential of €150
million per year (approx. $190 million pa).”
Bookmark this page